Stepan Co (NYSE: SCL) VP Sean Moriarty granted RSUs, performance shares and SARs
Filing Impact
Filing Sentiment
Form Type
4/A
Rhea-AI Filing Summary
STEPAN CO executive Sean Thomas Moriarty, VP & GM Surfactants, reported multiple equity-based compensation awards. On March 2, 2026, he received 4,495 restricted stock units, 2,247 performance shares, and 6,440 stock appreciation rights with a $50.06 exercise price. On February 27, 2026, he also acquired 56.765 shares of common stock as an award. The filing shows 14,205.2335 common shares held directly and 4,478.351 shares held indirectly through an ESOP II trust as of that date. This Form 4/A amends a prior filing solely to correct the stock appreciation right exercise price from $17.47 to $50.06; all other terms remain unchanged.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Moriarty Sean Thomas
Role
VP & GM Surfactants
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Appreciation Right | 6,440 | $0.00 | -- |
| Grant/Award | Performance Shares | 2,247 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 4,495 | $0.00 | -- |
| Grant/Award | Common Stock | 56.765 | $52.51 | $3K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Appreciation Right — 6,440 shares (Direct, null);
Performance Shares — 2,247 shares (Direct, null);
Restricted Stock Units — 4,495 shares (Direct, null);
Common Stock — 14,205.234 shares (Direct, null);
Common Stock — 4,478.351 shares (Indirect, By ESOP II Trust)
Footnotes (1)
- This Form 4/A amends the reporting person's original Form 4 filed on March 4, 2026 (the "Original Filing"). The Original Filing inadvertently reported an incorrect stock appreciation right ("SAR") conversion/exercise price due to an administrative error in the pricing calculation. The correct conversion/exercise price for the reported transaction is $50.06 not $17.47 as previously reported. This amendment corrects the reported conversion/exercise price. No other aspects of the reported transaction are affected. Vest ratably over three years beginning on the date shown. Each performance share represents a contingent right to receive one share of Stepan Company common stock. The performance shares vest upon the certification of Stepan Company achieving certain performance goals for the performance period ending December 31, 2028. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Stepan Company common stock.
Key Figures
Restricted stock units granted: 4,495 units
Performance shares granted: 2,247 shares
Stock appreciation rights granted: 6,440 rights
+4 more
7 metrics
Restricted stock units granted
4,495 units
Grant on March 2, 2026; vest over three years
Performance shares granted
2,247 shares
Grant on March 2, 2026; performance period to Dec. 31, 2028
Stock appreciation rights granted
6,440 rights
Grant on March 2, 2026; derivative award
SAR exercise price
$50.06 per share
Corrected from $17.47 in amended Form 4/A
Direct common shares after award
14,205.2335 shares
Direct holdings as of February 27, 2026
Indirect ESOP II Trust shares
4,478.351 shares
Indirect holdings as of February 27, 2026
Common stock award
56.765 shares at $52.51
Grant on February 27, 2026
Key Terms
Stock Appreciation Right, Restricted Stock Units, performance shares, Form 4/A, +1 more
5 terms
Stock Appreciation Right financial
"The correct conversion/exercise price for the reported transaction is $50.06"
A stock appreciation right (SAR) is a form of employee pay that gives the holder the right to receive the increase in a company's share price over a set reference price, paid in cash or shares, without having to buy stock first. It matters to investors because SARs can create future cash outflows or dilute existing shareholders if settled in stock, and they align employee incentives with share-price performance like a bonus tied to a home's price rise.
Restricted Stock Units financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Form 4/A regulatory
"This Form 4/A amends the reporting person's original Form 4 filed on March 4, 2026"
Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.
ESOP II Trust financial
"Common Stock ... 4478.3510 ... nature_of_ownership: By ESOP II Trust"
FAQ
What insider activity did STEPAN CO (SCL) report in this Form 4/A?
STEPAN CO reported equity compensation awards to executive Sean Thomas Moriarty. He received restricted stock units, performance shares, stock appreciation rights, and a small common stock grant, reflecting routine stock-based compensation rather than open-market buying or selling.
How many restricted stock units did Sean Moriarty receive at STEPAN CO (SCL)?
Sean Moriarty received 4,495 restricted stock units. Each RSU represents a contingent right to one share of Stepan Company common stock, vesting ratably over three years beginning on the grant date, according to the filing footnotes.
What are the key terms of Sean Moriarty’s stock appreciation rights at STEPAN CO (SCL)?
He was awarded 6,440 stock appreciation rights with a $50.06 exercise price. These rights are exercisable beginning March 2, 2027 and expire on March 3, 2036, providing potential value if the stock trades above the exercise price.
Why did STEPAN CO (SCL) file an amended Form 4/A for Sean Moriarty?
The amendment corrects an administrative error in the original filing. It changes the stock appreciation right exercise price from $17.47 to $50.06. The company states that no other aspects of the previously reported transaction are affected.